MA-MARIANA-ONCO/NOVARTIS
2.5.2024 13:01:28 CEST | Business Wire | Press release
Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis.
Mariana Oncology has developed a robust portfolio of novel peptide based-radiopharmaceuticals targeting a broad spectrum of solid tumor cancers, and has invested in manufacturing capabilities, an extensive isotope supply chain and novel formulations to enhance final product shelf-life. The company’s lead program, MC-339, is a novel radioligand therapy (RLT) designed to target small cell lung cancer.
“Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach. Together, we offer a compelling combination of capabilities,” said Simon Read, Founder and CEO, Mariana Oncology. “In the short time since founding the company, the team at Mariana Oncology has developed a leading radiopharmaceutical discovery platform and an innovative pipeline. Our strategy has centered on overcoming the unique challenges of end-to-end radiopharmaceutical R&D and ultimately, delivery of these drugs to the bedside. Both Mariana and Novartis are committed to transforming cancer care, and together we will be in a better position to do that.”
“This acquisition of Mariana Oncology brings to Novartis phenomenal talent and new capabilities in radioligand therapeutic research that complement our wide-ranging internal research and drug discovery efforts, in addition to our translational and clinical development capabilities,” said Shiva Malek, PhD, Global Head of Oncology for Biomedical Research at Novartis. “This is an ideal pairing, and we are thrilled to continue to do pioneering science together, translating RLT discovery into clinical development to deliver transformative therapies to patients.”
Mariana was founded in 2021 by Atlas Venture, Access Biotechnology and RA Capital Management, and has raised additional funds from other top investors including DeepTrack Capital and Forbion.
The transaction is subject to customary closing conditions.
Centerview Partners LLC served as financial advisor, and Goodwin Procter as legal counsel to Mariana Oncology on the transaction.
About Mariana Oncology
Mariana Oncology is a fully integrated, radiopharmaceutical company pioneering a new standard of care in cancer treatment – targeted peptide-based radioligand therapeutics (RLTs) designed to maximize tumor penetration while minimizing toxicity. Mariana is comprised of some of the world’s leading experts in radiopharmaceutical science and manufacturing who together are pioneering innovations in end-to-end discovery, development and delivery of radioligand therapeutics. The company has developed a portfolio of novel RLTs designed to target a broad range of difficult-to-treat cancers. Mariana’s lead program, MC-339, is an actinium-based radioligand therapeutic being investigated to treat small cell lung cancer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502315526/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIKE, Inc. Announces Planned CFO Transition23.6.2026 22:17:00 CEST | Press release
David M. Denton named incoming Chief Financial Officer NIKE, Inc. (NYSE:NKE) today announced that David M. Denton will join the company as Executive Vice President and Chief Financial Officer, effective August 17. Matthew Friend will step down as Executive Vice President and Chief Financial Officer at that time and remain with the company through September 4 to support an orderly transition. Friend will participate in the company’s fourth quarter fiscal 2026 earnings call on June 30, as planned. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623328558/en/ David M. Denton | Incoming Executive Vice President & Chief Financial Officer, NIKE, Inc. Denton will lead Nike’s global finance organization, partnering with President and Chief Executive Officer Elliott Hill and the Senior Leadership Team to support disciplined execution, capital allocation, and long-term value creation. “Dave is a proven public-company CFO who knows h
Grid Dynamics Hosted XT26, Convening Capital Markets Technology Leaders on the Volatility of AI in Financial Services23.6.2026 22:05:00 CEST | Press release
Key Takeaways: Grid Dynamics hosted XT26, an invite-only forum focused on the volatility of AI in financial services. XT26 attendees and speakers included over 250 senior technology leaders from global financial institutions such as Bank of America, Citi, HSBC, UBS, JP Morgan, Morgan Stanley, and others. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, hosted XT26. The invite-only conference convened over 250 senior technology leaders from banking, hedge funds, and capital markets at Tower Hill, London. Now in its 10th year, the XT conference series has grown into one of financial services engineering's most respected peer forums in London, built on a single premise: pure thought leadership grounded in real-world experience, with no sales pitches, and no vendor presentations. Just practitioners who are actually doing the work. This press release features multimedia. View the full release here: https://www.businessw
Thales Secures Significant U.S. Army LOCODA Radio Order Following Rapid Development Push23.6.2026 19:42:00 CEST | Press release
The U.S. Army has selected the Thales Radio Adaptable Transport (RAT) to support the Service’s Low Cost Data Architecture (LOCODA) tactical communications transformation effort. Rapidly developed and production ready, LOCODA RAT delivers scalable, modular, multi-transport voice and data connectivity designed to support evolving operational requirements across current and future mounted platforms. Built on a commercial-off-the-shelf and non-developmental item approach, LOCODA RAT scales production, supports continuous upgrades, and reduces integration complexity and lifecycle costs. Delivering capability at mission speed, Thales subsidiary, Thales Defense & Security, Inc. (TDSI), has secured an order for up to 5,000 Low Cost Data Architecture (LOCODA) Radio Adaptable Transport (RAT) platforms. The Thales RAT solution, which was conceived, developed and field-ready less than four months, modernizes voice and data communications and integrates effortlessly into radio mounts across all cur
Epicor Prism Launches Across European Markets, Bringing Embedded, Industry-Specific AI to Manufacturers23.6.2026 17:55:00 CEST | Press release
New AI capabilities help organisations enhance operational decision-making Epicor has expanded its AI-driven ERP strategy in the UK and select European markets with the general availability of Epicor Prism, a portfolio of vertical AI agents designed specifically for the supply chain industries. Embedded directly in Epicor Kinetic, Epicor Prism gives customers conversational access to live ERP data and related documents without needing specialised analytics skills or separate AI tools. The launch reflects a broader shift in ERP from systems of record to systems of outcomes that help users interpret data, make decisions and take action in real time — a transformation Epicor calls Cognitive ERP. Responding to pressure on productivity and skills European manufacturers are under growing pressure to raise productivity, strengthen supply chain resilience and remain globally competitive despite workforce constraints and ongoing digital skills shortages. While many organisations continue to inv
Airship Appoints Laura Zwahlen as Chief Revenue Officer23.6.2026 17:00:00 CEST | Press release
Go-To-Market and Revenue Operations Veteran to Lead Global Sales and Customer Success Organizations into the Next Phase of Growth Airship, the mobile-first customer experience company, today announced the appointment of Laura Zwahlen as Chief Revenue Officer (CRO). Zwahlen will oversee all global revenue-generating activities, driving the alignment, execution, and strategy across Airship’s sales, account management, and customer success teams to accelerate the company’s market leadership and customer impact. She will report directly to CEO Brett Caine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623145620/en/ Laura Zwahlen, Chief Revenue Officer (CRO) of Airship Zwahlen brings more than 20 years of go-to-market and revenue leadership experience, with a proven track record of guiding technology organizations through rapid growth, strategic acquisitions, and public offerings. Previously, she served as CRO at NextRoll (th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom